YU14701A - Nove hidratne forme natrijum alendronata, procesi njihovog dobijanja i njihov farmaceutski sastav - Google Patents

Nove hidratne forme natrijum alendronata, procesi njihovog dobijanja i njihov farmaceutski sastav

Info

Publication number
YU14701A
YU14701A YU14701A YU14701A YU14701A YU 14701 A YU14701 A YU 14701A YU 14701 A YU14701 A YU 14701A YU 14701 A YU14701 A YU 14701A YU 14701 A YU14701 A YU 14701A
Authority
YU
Yugoslavia
Prior art keywords
processes
alendronate sodium
pharmaceutical compositions
manufascture
hydrate forms
Prior art date
Application number
YU14701A
Other languages
English (en)
Inventor
Nina Finkelstein
Ramy Lidor-Hadas
Judith Aronhime
Original Assignee
Teva Pharmaceutical Industies Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industies Ltd. filed Critical Teva Pharmaceutical Industies Ltd.
Publication of YU14701A publication Critical patent/YU14701A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Zaštićeni su nova hidratna forma natrijum alendronata koja ima sadržaj vode izmedju oko jedan i oko dvanaest procenata i proces za njeno dobijanje. Takodje su zaštićene nove kristalne forme natrijum alendronata B, D, E, F, G i H i procesi za njihovo dobijanje. Nove forme natrijum alendronata pogodne su za inkorporaciju u farmaceutska jedinjenja za borbu protiv resorpcije kostiju u bolestima kostiju.[New hydrate forms of alendronate sodium, having water content of between about one and about twelve percent, and processes for their manufacture, are disclosed. New crystalline forms of alendronate sodium B, D, E, F, G and H, and processes for manufacturing them, are also disclosed. These new forms of alendronate sodium are suitable for incorporation into pharmaceutical compositions for combating bone resorption in bone diseases.
YU14701A 1998-08-27 1999-08-27 Nove hidratne forme natrijum alendronata, procesi njihovog dobijanja i njihov farmaceutski sastav YU14701A (sh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19

Publications (1)

Publication Number Publication Date
YU14701A true YU14701A (sh) 2003-01-31

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
YU14701A YU14701A (sh) 1998-08-27 1999-08-27 Nove hidratne forme natrijum alendronata, procesi njihovog dobijanja i njihov farmaceutski sastav

Country Status (30)

Country Link
US (2) US6281381B1 (sh)
EP (1) EP1107974B1 (sh)
JP (2) JP2002523514A (sh)
KR (2) KR20010079701A (sh)
AT (1) ATE334993T1 (sh)
AU (1) AU5698899A (sh)
BG (1) BG65329B1 (sh)
BR (1) BR9913472A (sh)
CA (1) CA2341459A1 (sh)
CZ (1) CZ2001629A3 (sh)
DE (1) DE69932620T2 (sh)
DK (1) DK1107974T3 (sh)
EA (1) EA002739B1 (sh)
EE (1) EE04552B1 (sh)
ES (1) ES2270613T3 (sh)
HR (1) HRP20010129A2 (sh)
HU (1) HUP0203078A3 (sh)
IL (1) IL141423A (sh)
IS (1) IS5864A (sh)
LT (1) LT4888B (sh)
LV (1) LV12720B (sh)
NO (1) NO20010957L (sh)
NZ (1) NZ510682A (sh)
PL (1) PL346347A1 (sh)
PT (1) PT1107974E (sh)
RO (1) RO122854B1 (sh)
SI (1) SI20581B (sh)
SK (1) SK2482001A3 (sh)
WO (1) WO2000012517A1 (sh)
YU (1) YU14701A (sh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455121T1 (de) * 2001-07-16 2010-01-15 Univ Paris 13 Herstellungsverfahren von derivate von bisphosphonaten
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
NZ552513A (en) * 2001-12-24 2008-08-29 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
CA2480814A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
WO2005035542A1 (en) * 2003-10-14 2005-04-21 Pliva-Istrazivanje I Razvoj D.O.O. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
SI1753395T1 (sl) 2004-05-24 2011-01-31 Warner Chilcott Co Llc Enterične trdne formulacije oralnih odmerkov bifosfonata, ki vsebuje kelirno sredstvo
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
CN101044188B (zh) * 2004-10-29 2010-08-04 桑多斯股份公司 制备格拉太咪尔的方法
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
BRPI0717394A2 (pt) * 2006-10-27 2013-10-15 Signal Pharm Llc Forma cristalina, composição farmacêutica, forma de dosagem unitária única, método para tratar ou prevenir uma doença ou condição, e, processo para preparar um composto
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) * 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
US5039819A (en) * 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
DK0833643T3 (da) * 1995-06-06 2005-05-30 Merck & Co Inc Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
JPH11506757A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 二ナトリウムアレンドロネート製剤

Also Published As

Publication number Publication date
IL141423A (en) 2005-09-25
LV12720A (lv) 2001-09-20
HUP0203078A3 (en) 2005-01-28
EE04552B1 (et) 2005-10-17
SI20581B (sl) 2008-06-30
IS5864A (is) 2001-02-26
ES2270613T3 (es) 2007-04-01
SI20581A (sl) 2001-12-31
KR20070034132A (ko) 2007-03-27
NO20010957L (no) 2001-04-26
LT4888B (lt) 2002-02-25
RO122854B1 (ro) 2010-03-30
JP2002523514A (ja) 2002-07-30
NZ510682A (en) 2003-09-26
KR20010079701A (ko) 2001-08-22
CZ2001629A3 (cs) 2001-08-15
JP2009143955A (ja) 2009-07-02
BG105292A (en) 2001-12-29
EP1107974A1 (en) 2001-06-20
DK1107974T3 (da) 2006-10-30
EA200100184A1 (ru) 2001-10-22
US6696601B2 (en) 2004-02-24
LV12720B (en) 2002-02-20
EP1107974A4 (en) 2001-09-26
ATE334993T1 (de) 2006-08-15
PT1107974E (pt) 2006-10-31
HUP0203078A2 (hu) 2003-01-28
BG65329B1 (bg) 2008-02-29
EA002739B1 (ru) 2002-08-29
WO2000012517A9 (en) 2000-07-13
US20030065214A1 (en) 2003-04-03
HRP20010129A2 (en) 2005-04-30
AU5698899A (en) 2000-03-21
WO2000012517A1 (en) 2000-03-09
EE200100126A (et) 2002-06-17
PL346347A1 (en) 2002-02-11
EP1107974B1 (en) 2006-08-02
NO20010957D0 (no) 2001-02-26
US6281381B1 (en) 2001-08-28
LT2001016A (en) 2001-10-25
DE69932620T2 (de) 2006-12-14
CA2341459A1 (en) 2000-03-09
DE69932620D1 (de) 2006-09-14
BR9913472A (pt) 2002-03-05
IL141423A0 (en) 2002-03-10
SK2482001A3 (en) 2002-01-07

Similar Documents

Publication Publication Date Title
PL346347A1 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
DE60038038D1 (en) Phosphonatverbindungen
MXPA02012904A (es) Nueva forma cristalina y de sal de ter-butilamina de perindopril, metodo de preparacion y composiciones farmaceuticas que contienen las mismas.
HUP0400781A3 (en) Process for the crystallization of (r)- or (s)-lansoprazole, the prepared crystalls and pharmaceutical compositions containing them and their use
ZA99913B (en) Alteration of amino acid compositions in seeds.
IL114641A (en) Pharmaceutical compositions containing dispersible fluoxetine
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
MY119970A (en) Method of fertilizing an avian egg in the shell
HUP0102813A3 (en) New betha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
HUP0401141A3 (en) Crystalline forms of fluvastatin sodium, process for their preparation and pharmaceutical compositions containing them
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
ZA200101451B (en) Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof.
WO2000076454A3 (fr) Compositions therapeutiques a usage ophtalmique et compositions therapeutiques destinees au traitement des lesions cerebrales centrales
IL110025A0 (en) Phosphonosuccinic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
MY118194A (en) Pharmaceutical compositions for use in inhibiting bone resorption
HUP9801781A3 (en) Process for producing indolil-methane compounds and pharmaceutical compositions for inhibiting transcriptase (rt) enzyme comprising the same compounds
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
HUP0102815A3 (en) New alpha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it